Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JAB-23E73 · 1 trial · 1 indication
A DLT is defined as any toxicities that meet the criteria for a DLT defined in the protocol
Incidence, and severity of adverse events and changes in clinical laboratory tests and examinations.
ORR, defined as the percentage of patients with the best overall response of confirmed partial response (PR), or complete response (CR) per RECIST v1.1.
Incidence, and severity of adverse events and changes in clinical laboratory tests and examinations. RP2D will be determined based on comprehensive available data
ORR, defined as the percentage of patients with the best overall response of confirmed PR, or CR per RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | JAB-23E73 monotherapy. |
| Part B1 | EXPERIMENTAL | JAB-23E73 combined with cetuximab |
| Name | Type | Description |
|---|---|---|
| JAB-23E73 | DRUG | Oral administration |
| Cetuximab | DRUG | Intravenous infusion |
Inclusion Criteria: * Written informed consent. * Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF). * Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions and who have receiv...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |